Combinations of serotonin receptor agonists for treatment of movement disorders
Inventors
Hansen, John Bondo • Thomsen, Mikael S.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9186359-B2
Publication Date
2015-11-17
Expiration Date
Abstract
The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.
Core Innovation
The described invention relates to methods for treatment or alleviation of a movement disorder selected from tardive dyskinesia, akathisia, Parkinson’s disease, and movement disorders associated with Parkinson’s disease. The methods administer a pharmaceutical composition to an individual in need thereof that includes a synergistically effective amount of a combination of zolmitriptan (or a pharmaceutically acceptable salt thereof) and buspirone (or a pharmaceutically acceptable salt thereof).
The disclosed approach is based on synergistically combined serotonergic 5-HT1 receptor agonism, particularly pairing a 5-HT1A agonist with an agonist active at 5-HT1B/5-HT1D and/or 5-HT1F receptors. Zolmitriptan is described as a 5-HT1B/5-HT1D active triptan and buspirone as a 5-HT1A agonist, with the intent of engaging multiple 5-HT1 receptor subtypes in a combined fashion.
The disclosed mechanism emphasizes modulation of dopamine neurotransmission in altered dopamine conditions to reduce L-DOPA-induced dyskinesia while aiming to avoid serotonin syndrome via dose reduction. The partial content further describes supporting biological testing and receptor activation assays used to support the reduction of central dopamine and associated abnormal involuntary movements in movement disorder models.
Claims Coverage
The independent claim identified is clm-00001. It covers a treatment or alleviation method for multiple listed movement disorders using a synergistically effective combination of zolmitriptan and buspirone as the core administered composition.
Synergistically effective zolmitriptan and buspirone administration
A method for treatment or alleviation of a movement disorder selected from tardive dyskinesia, akathisia, Parkinson's disease, and movement disorders associated with Parkinson's disease by administering a pharmaceutical composition comprising a synergistically effective amount of zolmitriptan (or a pharmaceutically acceptable salt thereof) and buspirone (or a pharmaceutically acceptable salt thereof) to an individual in need thereof.
Across the available independent claim coverage, the core inventive concept is the use of a synergistically effective combination of zolmitriptan (or a salt) and buspirone (or a salt) administered to treat or alleviate selected movement disorders, including tardive dyskinesia, akathisia, Parkinson’s disease, and movement disorders associated with Parkinson’s disease.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?